Gross K M, Bremner W J
Am J Med. 1987 Aug;83(2):359-61. doi: 10.1016/0002-9343(87)90713-3.
A 60-year-old man with stage D2 prostatic carcinoma received treatment with a new luteinizing hormone-releasing hormone superagonist. After a seven-month remission; relapse of the disease occurred and an adrenal-suppressing dose of dexamethasone was added. The resulting combined gonadal and adrenal suppression led to another remission that lasted five months. This case supports other observations of the importance of adrenal androgen production in the pathobiology of prostatic carcinoma.
一名患有D2期前列腺癌的60岁男性接受了一种新型促黄体生成激素释放激素超级激动剂的治疗。经过七个月的缓解期后,疾病复发,遂加用了能抑制肾上腺功能的地塞米松剂量。由此产生的性腺和肾上腺联合抑制导致了另一次持续五个月的缓解期。该病例支持了其他关于肾上腺雄激素产生在前列腺癌病理生物学中的重要性的观察结果。